 The first thing I want to start with, which is a popular question, probably one of the most common I get is, what is the evidence of cannabinoid activity or THC in Cleoblastoma, multi-form or GBM specifically? It is a common question, and you can tell when you Google that question, you'll get lots of hits. And while depending on where you go, when you type in that question, you might get a slightly different answer. But the general takeaway, believe it or not, is there's good reason and good science to believe that cannabinoids, whether it's THC, CBD, or others, actually have a positive effect on Cleoblastoma, either alone but also in combination with the standard of care, which is often radiation therapy or a temozolamide or a combination of both, etc. So there is existing evidence that both THC and CBD can have positive impacts on GBM, which is pretty astounding because this is a very difficult to treat disease. It does not respond to typical chemotherapeutic agents, which then starts to question, well, why would it work? Why would that happen? Well, it goes back to that endocannabinoid system. So glial cells, which is actually a term for multiple different brain cells, are generally covered in cannabinoid receptors, the satellite dishes that normally receive the endocannabinoid signal. They are very abundant. In fact, I haven't mentioned this yet, but cannabinoid receptors, CB1, the one that THC acts on to get as high, is actually the most abundant receptor in the brain. There are multiple studies that have confirmed this now. It is more abundant than any of the other receptors that we've talked about or that have been identified. This is everywhere in our nervous system because the nervous system needs to be in check and in balance. And if it's not, you're getting inappropriate signals, so you're perceiving the world wrong, whether that means pain, whether that means schizophrenia, but the receptors that drive the effects of cannabis are extremely abundant in brain cells, which is where glioblastoma tends to be.